encorafenib and binimetinib

Generic Name: encorafenib and binimetinib

Brand Name: Braftovi and Mektovi

Manufacturer: Pfizer Canada ULC

Therapeutic Area: Advanced Melanoma

Indications: ​Braftovi (encorafenib): In combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test. Mektovi (binimetinib): In combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test.

Manufacturer Requested Reimbursement Criteria¹: Braftovi (encorafenib): In combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test. Mektovi (binimetinib): In combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test.

Submission Type: Initial

Tumour Type: Skin & Melanoma

NOC Status at Filing: Pre NOC

Project Status: Active

Companion Diagnostics: Yes

Fee Schedule¹: Schedule A

1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.